Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could laughing gas stop suicidal urges in minutes?

NCT ID NCT05710887

Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a single 45-minute dose of inhaled nitrous oxide (laughing gas) could quickly reduce suicidal thoughts and depression in people visiting the emergency department. It was designed for adults aged 18-65 with major depressive disorder who were actively suicidal. The study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Started

Feb 2026

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18-65 years of age, acutely suicidal, presenting to the adult emergency department with documented history of non-psychotic major depressive disorder. Exclusion Criteria: * Current psychotic or catatonic symptoms as determined by the hospital care team. * Unable or unwilling to give consent for study participation (ability to provide consent will be established by treating physician) * Lifetime DSM-V (medical history) diagnoses of schizophrenia, schizoaffective disorders, bipolar disorder, obsessive-compulsive disorder, and panic disorders. * Meets current DSM-V substance use disorder of greater than mild severity (other than nicotine or marijuana) * Significant pulmonary disease and/or requiring supplemental oxygen. * Administration of other NMDA-receptor antagonist treatment (e.g., ketamine) within two weeks of entry into study. * Contraindications for N2O (pneumothorax, bowel obstruction, middle ear occlusion, elevated intracranial pressure) * Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12. * Women who are pregnant or breastfeeding * Any other factor that in the investigators' judgment may affect patient safety or compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression Depressive Disorder, Treatment-Resistant major depressive disorder Suicidal Ideation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder Suicidal ideation Treatment-resistant depression

Contacts and locations

Locations

  • University of Chicago Medicine

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.